Dr. Patrick Dealmeida, DO

Dr. Dealmeida practices at Jersey City Medical Center in Jersey City, New Jersey, part of RWJBarnabas Health.

Dr. Dealmeida's NPI, 1851772008, was assigned on June 13, 2015. Dr. Dealmeida holds New Jersey license 25MB10168800.

Dr. Dealmeida's primary practice is Jersey City Medical Center, at 355 Grand Street, Jersey City, NJ 07302 in Hudson County. The practice phone is (201) 915-2000.

Dr. Dealmeida's primary practice is Jersey City Medical Center in Jersey City, New Jersey, part of RWJBarnabas Health. Dr. Dealmeida is also affiliated with Robert Wood Johnson University Hospital. The medical group on file is RWJBarnabas Health Medical Group. Dmand AI also links Dr. Dealmeida to 2 more hospitals, 4 medical groups, 1 group practice or clinic, 1 hospice and 1 skilled nursing facility, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dealmeida practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Dealmeida's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Dealmeida is licensed in New Jersey.

CMS data shows 1,189 Medicare services from Dr. Dealmeida across 9 procedure codes in 2024, for 490 Medicare patients. Medicare paid $119,601 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 490 Medicare patients who saw Dr. Dealmeida in 2024. The largest group is 75 to 84, with 155 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 33% are also on Medicaid. Their average risk score is 2.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dealmeida's median patient age at 76, with 51% women.

In 2024, Dr. Dealmeida wrote 407 Medicare Part D claims for 121 patients. 86% of them were for generic drugs. CMS names the drug for 165 of them, across 11 drugs with 11 or more claims each, at $9,179 in total drug cost. In 2022, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Dealmeida for performance year 2024, reported as part of a group. Dr. Dealmeida accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 93 general payments to Dr. Dealmeida from 7 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) paid the most, $1,029.